World Pharmaceutical Frontiers

4 days ago | worldpharmaceuticals.net | Vidya Sagar Maddela

US-based biotechnology company Tempus has announced a strategic collaboration with AstraZeneca and Pathos to develop a multimodal foundation model in oncology. The partnership aims to leverage Tempus’ AI capabilities and oncology data to generate biological and clinical insights, discover novel drug targets, and develop cancer therapeutics. The foundation model will be shared among all three parties to enhance patient care.

4 days ago | worldpharmaceuticals.net | Vidya Sagar Maddela

US-based biotechnology company Repertoire Immune Medicines has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche Group. The collaboration aims to develop T cell-targeted therapies for an autoimmune disease. Under the partnership, Repertoire will use its DECODE platform to identify new targets. Genentech will be responsible for preclinical and clinical development, and global commercialisation of the T cell-targeted therapies.

5 days ago | worldpharmaceuticals.net | Swagath Bandhakavi

Switzerland-based Roche has announced plans to invest $50bn in the US over the next five years, in a move to reinforce its presence in the country across both its pharmaceuticals and diagnostics divisions. The decision is expected to create over 12,000 new jobs, including approximately 6,500 in construction and 1,000 within new and expanded company facilities.

5 days ago | worldpharmaceuticals.net | Vidya Sagar Maddela

TNF Pharmaceuticals and Renova Health have announced the use of artificial intelligence (AI) and machine learning (ML) technologies to speed up drug development. The collaboration aims to identify high-risk patients who could benefit from preserving lean muscle mass during GLP-1 treatment for diabetes, weight loss, and weight management. Renova Health’s AI technology, comprising advanced natural language processing and large language models, enables TNF Pharma to analyse data from 30,000 patients.

5 days ago | worldpharmaceuticals.net | Vidya Sagar Maddela

ConcertAI has entered a multi-year partnership with Bayer to advance precision oncology through its Translational360 and AI SaaS solutions. The solutions, driven by artificial intelligence and machine learning (AI/ML) insights, aim to expedite clinical development in precision oncology. The collaboration will fully leverage ConcertAI’s Translational360, a newly launched integrated research-grade longitudinal clinical molecular database.